EZH2 and melanoma: Therefore, to mimic the clinical scenario, we conducted a long-term clonogenic survival assay using GSK343 (targeting EZH2), JQ1 (targeting BET family BRD proteins-BRD2 and BRD3), TP-472 (targeting BRD7/9) using multiple BRAF mutant melanoma cell lines (M14, SKMEL-28, A375, and A2058).